• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Expert opinion on biological therapy >New therapeutic agents for the treatment of bone diseases.
【24h】

New therapeutic agents for the treatment of bone diseases.

机译：用于治疗骨疾病的新型治疗剂。

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Bisphosphonates have demonstrated important clinical benefits for patients with malignant bone disease, metabolic bone diseases, such as Paget's disease, and postmenopausal osteoporosis. The introduction of nitrogen-containing bisphosphonates with high affinity for hydroxyapatite in bone represents an important advancement. These agents are now a standard of care for osteoporosis, Paget's disease, osteogenesis imperfecta, primary bone lesions from multiple myeloma and bone metastases from breast cancer. Moreover, the recent clinical development of zoledronic acid (4 mg by 15-minute intravenous infusion) has expanded the benefits of bisphosphonate therapy to patients with bone metastases from any solid tumour. Bisphosphonates are also being investigated at present for the prevention of bone loss resulting from cancer therapy. In addition, a variety of novel biologic agents, receptor activator of nuclear factor-kappaB (RANK) ligand antibodies, osteoprotegerin and cathepsin K inhibitors are being investigated at present for the treatment of malignant bone disease. The management of bone health is an important area of active research, and the armamentarium and role of bone-specific therapies continue to expand.
机译：双膦酸盐已证明对患有恶性骨病，代谢性骨病（如Paget病）和绝经后骨质疏松症的患者具有重要的临床益处。对骨骼中羟基磷灰石具有高亲和力的含氮双膦酸盐的引入代表了重要的进展。这些药物现已成为治疗骨质疏松症，佩吉特氏病，成骨不全症，多发性骨髓瘤引起的原发性骨病变和乳腺癌引起的骨转移的标准治疗方法。此外，唑来膦酸的最新临床发展（静脉内输注15分钟，剂量为4 mg）已将双膦酸盐治疗的益处扩展至患有任何实体瘤的骨转移患者。目前也正在研究双膦酸盐用于预防癌症治疗引起的骨质流失。另外，目前正在研究用于治疗恶性骨疾病的各种新型生物制剂，核因子-κB（RANK）配体抗体的受体激活剂，骨保护素和组织蛋白酶K抑制剂。骨骼健康的管理是积极研究的重要领域，并且骨骼专用疗法的武器库和作用在不断扩大。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号